Predictive Model for Idiopathic Multicentric Castleman Disease Supporting Treatment Decisions
Open Access
- 20 November 2020
- journal article
- editorial
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 26 (1), 4-6
- https://doi.org/10.1002/onco.13605
Abstract
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.Keywords
This publication has 17 references indexed in Scilit:
- Novel insights and therapeutic approaches in idiopathic multicentric Castleman diseaseBlood, 2018
- International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman diseaseBlood, 2018
- Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomasBlood Advances, 2018
- Idiopathic multicentric Castleman's disease: a systematic literature reviewThe Lancet Haematology, 2016
- Use of a claims database to characterize and estimate the incidence rate for Castleman diseaseLeukemia & Lymphoma, 2014
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2014
- HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapyBlood, 2014
- The clinical spectrum of Castleman's diseaseAmerican Journal of Hematology, 2012
- Castleman's Disease: Systematic Analysis of 416 Patients from the LiteratureThe Oncologist, 2011
- The management of unicentric and multicentric Castleman's diseaseCancer, 1999